1. Home
  2. Live Updates
  3. Yale cancer center

Live Breaking News & Updates on Yale Cancer Center

Stay updated with breaking news from Yale cancer center. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Luspatercept Generates Across-the-Board Benefit for Lower-Risk MDS in COMMANDS

Luspatercept elicited superior erythroid response rates and duration of RBC transfusion independence compared with epoetin alfa in lower-risk MDS. ....

Connecticut , United-states , New-haven , Samer-zeidan , International-working-group , Yale-school-of-medicine , International-prognostic-scoring-system , Yale-cancer-center , Yale-school , Revised-international-prognostic-scoring ,

Dr Kunz on Time to Response With Lutetium Lu 177 Dotatate in GEP-NETs

Pamela L. Kunz, MD, discusses a subanalysis of the NETTER-2 study investigating frontline lutetium Lu 177 dotatate in advanced, well-differentiated GEP-NETs. ....

Pamelal-kunz , Yale-school-of-medicine , Yale-cancer-center , Yale-school , Smilow-cancer-hospital ,

First time Closer to Free rider prepares to ride 100 miles for his son

We are getting closer to an event near and dear to NBC Connecticut. The 14th Closer to Free Ride is just under three months away. The ride draws thousands to. ....

Connecticut , United-states , New-haven , Yale-new-haven-hospital , Sean-nolan , Joseph-bowman , Tommy-fund , Tommy , Yale-cancer-center , Free-ride , Smilow-cancer-hospital , Yale-new-haven-children

Trastuzumab Deruxtecan Prolongs PFS in Pretreated HR+, HER2-Low and -Ultralow Metastatic Breast Cancer

Trastuzumab deruxtecan improved PFS vs chemotherapy in pretreated, HR-positive, HER2-low or -ultralow metastatic breast cancer. ....

Connecticut , United-states , New-haven , Daiichi-sankyo , Daichii-sankyo , Roche-genentech , Ian-krop , Bristol-myers-squibb , Glaxosmithkline , European-society-of-breast-cancer-specialists , Pfizer , Guardant-health

Enhertu Boosts PFS in Pretreated, HR-Positive, HER2-Low and -Ultralow Breast Cancer

Enhertu lengthened the time to progression in patients with HR-positive, HER2-low or -ultralow metastatic breast cancer. ....

Milan , Lombardia , Italy , New-haven , Connecticut , United-states , Giuseppe-curigliano , Ian-krop , European-institute-of-oncology , Clinical-sciences-at-yale-cancer-center , University-of-milan , Clinical-trials-office